New vaccine aims to clear HPV and reverse cervical precancer
NCT ID NCT07454915
Summary
This study is testing an experimental vaccine called PVX4 to see if it can help the body clear HPV16 infection and reverse high-grade precancerous cervical lesions (CIN2/3). It will enroll about 138 women aged 18-60 who have confirmed HPV16+ CIN2/3 and compare the vaccine to a placebo. The main goal is to see if the vaccine leads to clearance of the virus and regression of the lesions within 6 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS INFECTION TYPE 16 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China Medical University Hospital
Taichung, Taiwan, 40447, Taiwan
-
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, Taiwan, 83301, Taiwan
-
Linkou Chang Gung Memorial Hospital
Taoyuan District, Taiwan, 33305, Taiwan
Contact
-
MacKay Memorial Hospital
Taipei, Taiwan, 10449, Taiwan
Contact
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
Contact
-
National Cheng Kung University Hospital
Tainan, Taiwan, 70403, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan, 100225, Taiwan
Contact
-
Taichung Veterans General Hospital
Taichung, Taiwan, 40705, Taiwan
-
Taipei Medical University Hospital
Taipei, Taiwan, 11031, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan, 11217, Taiwan
Conditions
Explore the condition pages connected to this study.